Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Pediatr Transplant ; 27(3): e14459, 2023 05.
Artigo em Inglês | MEDLINE | ID: mdl-36597218

RESUMO

BACKGROUND: ABO-incompatible heart transplantation (HTx) has become a standard procedure for children below 2 years of age due to an immunologically immature immune system and associated low isohemagglutinin titers. METHODS: We report a case of an ABO-incompatible HTx (recipient blood group O, donor blood group A) at the age of 5 years and 11 months with a fully matured immune system and previously high isohemagglutinin titers that diminished as a result of human leucocyte antigen (HLA) desensitization therapy with rituximab and immunoglobulins. RESULTS: The anti-A titer at the time of HTx was 1:16 with post-transplant isoagglutinin titers never exceeding 1:4 without any signs of rejection with now 3 years of post-HTx follow-up. CONCLUSIONS: ABO isohemagglutinin titers should be routinely assessed in children undergoing desensitization therapy since ABOi transplantation can be considered in selected cases to expand the donor pool with the option of crossing the ABO barrier to find a better-matched allograft.


Assuntos
Transplante de Coração , Hemaglutininas , Humanos , Criança , Adolescente , Pré-Escolar , Doadores Vivos , Rituximab/uso terapêutico , Incompatibilidade de Grupos Sanguíneos , Rejeição de Enxerto , Sistema ABO de Grupos Sanguíneos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...